Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Bobby Berry who wrote (535)	12/23/1997 1:49:00 PM
From: james	Read Replies (1) \| Respond to of 975

Bobby, the news acturally made to Reuters too. It seems to be a "naturally-occurring small molecule". I didn't know blsi had (association with) a natural extract screening program, or did they? I'll wait & read its paper. These days in biotech (& everything else), good news equal no news, & bad news equal epitaph. I gather that this means 'bottoming-out'. james =============================================================== Tuesday December 23, 12:37 pm Eastern Time Boston Life finds 2nd nerve growth factor BOSTON, Dec 23 (Reuters) - Boston Life Sciences Inc said Tuesday that its scientists have discovered that a naturally-occurring small molecule appears to strongly stimulate axonal regeneration in nerve cells of the central nervous system (CNS). This molecule is the second apparent CNS axonal growth factor to be identified as part of the company's CNS nerve regeneration program. ''We believe that the fundamental importance of this new work is that it demonstrates that neurons in the CNS may be actually capable of regenerating axonal connections between cells in response to certain endogenous growth factors in mammals,'' said Marc Lanser, chief scientific officer, in a press release. The company said that it is studying this and its first axonal growth factor in spinal cord injury models, and if test results warrant, it hopes to complete preclinical testing and file an Investigational New Drug (IND) application for one or both compounds as soon as possible. ==================================